1
|
Sun R, Li X, Liu M, Zeng Y, Chen S and
Zhang P: Advances in stem cell therapy for cardiovascular disease
(Review). Int J Mol Med. 38:23–29. 2016. View Article : Google Scholar : PubMed/NCBI
|
2
|
Zhang C, Nong Y, Tong S, Yao Q, Wen L,
Zhang Z, Wei L, Cheng J, Feng Y and Song Z: Triptolide improves
early survival of mesenchymal stem cells transplantation into rat
myocardium. Cardiology. 128:73–85. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Choi SH, Jung SY, Kwon SM and Baek SH:
Perspectives on stem cell therapy for cardiac regeneration:
Advances and challenges. Circ J. 76:1307–1312. 2012. View Article : Google Scholar : PubMed/NCBI
|
4
|
Chin SP, Poey AC, Wong CY, Chang SK, Tan
CS, Ng MT, Chew KH, Lam KH and Cheong SK: Intramyocardial and
intracoronary autologous bone marrow-derived mesenchymal stromal
cell treatment in chronic severe dilated cardiomyopathy.
Cytotherapy. 13:814–821. 2011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Suresh SC, Selvaraju V, Thirunavukkarasu
M, Goldman JW, Husain A, Palesty Alexander J, Sanchez JA, McFadden
DW and Maulik N: Thioredoxin-1 (Trx1) engineered mesenchymal stem
cell therapy increased pro-angiogenic factors, reduced fibrosis and
improved heart function in the infracted rat myocardium. Int J
Cardiol. 201:517–528. 2015. View Article : Google Scholar : PubMed/NCBI
|
6
|
Li L, Zhang Y, Li Y, Yu B, Xu Y, Zhao S
and Guan Z: Mesenchymal stem cell transplantation attenuates
cardiac fibrosis associated with isoproterenol-induced global heart
failure. Transpl Int. 21:1181–1189. 2008. View Article : Google Scholar : PubMed/NCBI
|
7
|
Li L, Zhang S, Zhang Y, Yu B, Xu Y and
Guan Z: Paracrine action mediate the antifibrotic effect of
transplanted mesenchymal stem cells in a rat model of global heart
failure. Mol Biol Rep. 36:725–731. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Xu B, Luo Y, Liu Y, Li BY and Wang Y:
Platelet-derived growth factor-BB enhances MSC-mediated
cardioprotection via suppression of miR-320 expression. Am J
Physiol Heart Circ Physiol. 308:H980–H989. 2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Wen Z, Huang W, Feng Y, Cai W, Wang Y,
Wang X, Liang J, Wani M, Chen J, Zhu P, et al: MicroRNA-377
regulates mesenchymal stem cell-induced angiogenesis in ischemic
hearts by targeting VEGF. PLoS One. 9:e1046662014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Tsuruda T, Kato J, Kitamura K, Kawamoto M,
Kuwasako K, Imamura T, Koiwaya Y, Tsuji T, Kangawa K and Eto T: An
autocrine or a paracrine role of adrenomedullin in modulating
cardiac fibroblast growth. Cardiovasc Res. 43:958–967. 1999.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Horio T, Nishikimi T, Yoshihara F, Matsuo
H, Takishita S and Kangawa K: Effects of adrenomedullin on cultured
rat cardiac myocytes and fibroblasts. Eur J Pharmacol. 382:1–9.
1999. View Article : Google Scholar : PubMed/NCBI
|
12
|
Nishikimi T, Yoshihara F, Mori Y, Kangawa
K and Matsuoka H: Cardioprotective effect of adrenomedullin in
heart failure. Hypertens Res. 26 Suppl:S121–S127. 2003. View Article : Google Scholar : PubMed/NCBI
|
13
|
Okumura H, Nagaya N and Kangawa K:
Adrenomedullin infusion during ischemia/reperfusion attenuates left
ventricular remodeling and myocardial fibrosis in rats. Hypertens
Res. 26 Suppl:S99–S104. 2003. View Article : Google Scholar : PubMed/NCBI
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Okuda N, Hayashi T, Mori T, Inamoto S,
Okabe M, Mieno S, Horimoto H and Kitaura Y: Nifedipine enhances the
cardioprotective effect of an angiotensin-II receptor blocker in an
experimental animal model of heart failure. Hypertens Res.
28:431–438. 2005. View Article : Google Scholar : PubMed/NCBI
|
16
|
Teerlink JR, Pfeffer JM and Pfeffer MA:
Progressive ventricular remodeling in response to diffuse
isoproterenol-induced myocardial necrosis in rats. Circ Res.
75:105–113. 1994. View Article : Google Scholar : PubMed/NCBI
|
17
|
Brouri F, Hanoun N, Mediani O, Saurini F,
Hamon M, Vanhoutte PM and Lechat P: Blockade of beta1- and
desensitization of beta 2-adrenoceptors reduce isoprenaline-induced
cardiac fibrosis. Eur J Pharmacol. 485:227–234. 2004. View Article : Google Scholar : PubMed/NCBI
|
18
|
Maisch B: Ventricular remodeling.
Cardiology. 87 Suppl 1:S2–S10. 1996. View Article : Google Scholar
|
19
|
Eckhouse SR and Spinale FG: Changes in the
myocardial interstitium and contribution to the progression of
heart failure. Heart Fail Clin. 8:7–20. 2012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Deschamps AM and Spinale FG: Matrix
modulation and heart failure: New concepts question old beliefs.
Curr Opin Cardiol. 20:211–216. 2005. View Article : Google Scholar : PubMed/NCBI
|
21
|
Spinale FG: Myocardial matrix remodeling
and the matrix metalloproteinases: Influence on cardiac form and
function. Physiol Rev. 87:1285–1342. 2007. View Article : Google Scholar : PubMed/NCBI
|
22
|
Vanhoutte D, Schellings M, Pinto Y and
Heymans S: Relevance of matrix metalloproteinases and their
inhibitors after myocardial infarction: A temporal and spatial
window. Cardiovasc Res. 69:604–613. 2006. View Article : Google Scholar : PubMed/NCBI
|
23
|
Song YH, Cai H, Gu N, Qian CF, Cao SP and
Zhao ZM: Icariin attenuates cardiac remodelling through
down-regulating myocardial apoptosis and matrix metalloproteinase
activity in rats with congestive heart failure. J Pharm Pharmacol.
63:541–549. 2001. View Article : Google Scholar
|
24
|
Creemers EE, Cleutjens JP, Smits JF and
Daemen MJ: Matrix metalloproteinase inhibition after myocardial
infarction: A new approach to prevent heart failure? Circ Res.
89:201–210. 2001. View Article : Google Scholar : PubMed/NCBI
|
25
|
Li YY, McTiernan CF and Feldman AM:
Interplay of matrix metalloproteinases, tissue inhibitors of
metalloproteinases and their regulators in cardiac matrix
remodeling. Cardiovasc Res. 46:214–224. 2000. View Article : Google Scholar : PubMed/NCBI
|
26
|
Boixel C, Fontaine V, Rücker-Martin C,
Milliez P, Louedec L, Michel JB, Jacob MP and Hatem SN: Fibrosis of
the left atria during progression of heart failure is associated
with increased matrix metalloproteinases in the rat. J Am Coll
Cardiol. 42:336–344. 2003. View Article : Google Scholar : PubMed/NCBI
|
27
|
Wang Y, Zhang JS, Qian J, Huang GC and
Chen Q: Adrenomedullin regulates expressions of transforming growth
factor-beta1 and beta1-induced matrix metalloproteinase-2 in
hepatic stellate cells. Int J Exp Pathol. 87:177–184. 2006.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Lee EG, Lee S, Chae HJ, Park SJ, Lee YC
and Yoo WH: Adrenomedullin inhibits IL-1β-induced rheumatoid
synovial fibroblast proliferation and MMPs, COX-2 and PGE2
production. Inflammation. 34:335–343. 2011. View Article : Google Scholar : PubMed/NCBI
|
29
|
Li Y, Takemura G, Kosai K, Yuge K, Nagano
S, Esaki M, Goto K, Takahashi T, Hayakawa K, Koda M, et al:
Postinfarction treatment with an adenoviral vector expressing
hepatocyte growth factor relieves chronic left ventricular
remodeling and dysfunction in mice. Circulation. 107:2499–2506.
2003. View Article : Google Scholar : PubMed/NCBI
|
30
|
Edgley AJ, Krum H and Kelly DJ: Targeting
fibrosis for the treatment of heart failure: A role for
transforming growth factor-β. Cardiovasc Ther. 30:e30–e40. 2012.
View Article : Google Scholar : PubMed/NCBI
|